By: T. Feys MBA, MSc
This final article discussing highlights from SABCS 2022 summarizes some of the presentations that did not fit in the categories discussed earlier. This summary will address the results of three clinical trials evaluating neoadjuvant treatment strategies in HER2-negative early breast cancer together with the data from the POSITIVE trial, evaluating the safety of interrupting endocrine therapy to facilitate pregnancy panning in younger women with breast cancer.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
